文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

CAR-T细胞治疗后继发第二原发肿瘤的风险与管理策略

[The risk and management strategies for second primary tumor after CAR-T cell therapy].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

本文综述CAR-T细胞治疗后继发第二原发肿瘤(SPM)的长期安全性问题,指出2年累计发生率约0.08%~8%,中位发生时间9.7~26.4个月,以髓系恶性肿瘤为主。机制涉及载体基因组整合、既往治疗遗传毒性、免疫失衡及克隆性造血,未来需完善全流程管理以降低风险。

要点

  • CAR-T后SPM的2年累计发生率为0.08%~8%,中位发生时间9.7~26.4个月。
  • SPM以治疗相关髓系恶性肿瘤(MDS、AML)为主,实体瘤和T细胞淋巴瘤少见。
  • 建议治疗前遗传风险筛查和治疗后长期系统监测以优化全流程管理。

核心结论

  • CAR-T细胞治疗后继发第二原发肿瘤(SPM)风险因类型而异,需通过全流程管理将其控制在最低水平以保证长期安全性。

研究设计与样本

  • 本文为综述,汇总CAR-T细胞治疗后SPM的现有临床与转化研究证据。

主要发现

  • CAR-T后SPM的2年累计发生率为0.08%~8%,中位发生时间为9.7~26.4个月。
  • SPM主要类型为治疗相关髓系恶性肿瘤如骨髓增生异常综合征和急性髓系白血病,另有实体瘤及少数T细胞淋巴瘤。
  • 仅在极少数T细胞淋巴瘤病例中检测到CAR转基因。
  • 机制涉及病毒载体相关基因组整合风险、既往化疗或造血干细胞移植的遗传毒性损伤、免疫失衡和克隆性造血扩增。

临床怎么用

  • 未来可开发更安全的基因编辑技术、将CAR-T治疗前移以减少前期治疗累积毒性。
  • 开展治疗前遗传风险筛查以及治疗后长期系统性监测,完善全流程管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized the treatment of refractory hematologic malignancies, but its long-term safety has become an increasing concern. Secondary primary malignancies (SPM) following CAR-T-cell therapy have emerged as a growing focus of clinical and translational research. Evidence to date suggests that the incidence of different types of SPMs vary, with a two-year cumulative incidence ranging from approximately 0.08% to 8% and a median time to onset of 9.7 to 26.4 months, predominantly involving myeloid malignancies such as myelodysplastic syndromes and acute myeloid leukemia, while solid tumors and rare T-cell lymphomas have also been reported. CAR transgenes have been detected in only a minority of T-cell lymphoma cases. The mechanisms involved vector-related genomic integration risks, genotoxic stress from prior chemotherapy or hematopoietic stem cell transplantation, immune dysregulation, and clonal hematopoietic expansion. Future research may focus on developing safer gene-editing technologies, moving CAR-T-cell therapy to earlier treatment lines to reduce cumulative toxicity from prior therapies, implementing genetic risk screening before treatment, and establishing long-term systematic monitoring after therapy. By optimizing full-process management, the risk of SPM can be minimized, thereby improving the long-term safety of CAR-T-cell therapy while maintaining its therapeutic efficacy. 嵌合抗原受体T(CAR-T)细胞治疗在难治性血液系统肿瘤中取得了突破性进展,但其长期安全性日益受到重视,CAR-T细胞治疗后继发肿瘤(第二原发肿瘤,SPM)成为临床与基础研究的焦点。现有研究显示,CAR-T细胞治疗后不同类型SPM发生风险存在差异,2年累计发生率为0.08%~8%,中位发生时间为9.7~26.4个月。治疗相关骨髓增生异常综合征、急性髓系白血病等髓系恶性肿瘤为SPM主要类型,此外还包括实体瘤及少数T细胞淋巴瘤;仅在极少数T细胞淋巴瘤病例中检测到CAR转基因。其发生机制涉及病毒载体相关基因组整合风险、既往化疗或造血干细胞移植导致的遗传毒性损伤,以及免疫失衡和克隆性造血扩增等因素。未来研究可聚焦于开发更安全的基因编辑技术、将CAR-T细胞治疗前移以减少前期治疗的累积毒性,开展治疗前的遗传风险筛查以及治疗后的长期系统性监测,完善全流程管理将SPM发生风险控制在最低水平,从而在保证疗效的同时提升CAR-T细胞治疗的长期安全性。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li RN, Wang WY, Yang F, et al. [The risk and management strategies for second primary tumor after CAR-T cell therapy]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42851188. doi:10.3760/cma.j.cn121090-20260118-00036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。